Clinical data | |
---|---|
Trade names | Actos, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a699016 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Thiazolidinedione |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | >99% |
Metabolism | Liver (CYP2C8) |
Elimination half-life | 3–7 hours |
Excretion | Bile duct |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.114.441 |
Chemical and physical data | |
Formula | C19H20N2O3S |
Molar mass | 356.44 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
Melting point | 183 to 184 °C (361 to 363 °F) |
| |
| |
(verify) |
Pioglitazone, sold under the brand name Actos among others, is an anti-diabetic medication used to treat type 2 diabetes.[3] It may be used with metformin, a sulfonylurea, or insulin.[3][4] Use is recommended together with exercise and diet.[4] It is not recommended in type 1 diabetes.[4] It is taken by mouth.[4]
Common side effects include headaches, muscle pains, inflammation of the throat, and swelling.[4] Serious side effects may include bladder cancer, low blood sugar, heart failure, and osteoporosis.[4][3] Use is not recommended in pregnancy or breastfeeding.[3] It is in the thiazolidinedione (TZD) class and works by improving sensitivity of tissues to insulin.[3]
Pioglitazone was patented in 1985, and came into medical use in 1999.[5] It is available as a generic medication.[3] In 2022, it was the 120th most commonly prescribed medication in the United States, with more than 5 million prescriptions.[6][7] It was withdrawn in France and Germany in 2011.[8][9][10]
Actos FDA label
was invoked but never defined (see the help page).FDA safety
was invoked but never defined (see the help page).